Search

Your search keyword '"Jeffrey P. Sharman"' showing total 12 results
Start Over Author "Jeffrey P. Sharman" Publisher wiley
12 results on '"Jeffrey P. Sharman"'

1. A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

Author

Jeffrey P. Sharman, Juliana M. L. Biondo, Michelle Boyer, Kirsten Fischer, Michael Hallek, Dingfeng Jiang, Arnon P. Kater, Michele Porro Lurà, and William G. Wierda

Subjects
chronic lymphocytic leukemia, debulking, hospitalization, tumor lysis syndrome, venetoclax, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract We reviewed the literature (January 2010–June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk, and avoid hospitalization. Low TLS incidence and reduced TLS risk based on tumor burden were reported following debulking in clinical trials. Real‐world observational studies reporting debulking regimens recorded no TLS events, and those without debulking strategies had greater TLS incidence. Debulking prior to venetoclax considerably reduces TLS incidence. Further clinical trials and real‐world studies may provide additional evidence on effectiveness of debulking in reducing TLS incidence and hospitalization need.

Published
2022
Full Text
View/download PDF

2. INDUCTION R 2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY

Author

Mecide Gharibo, Jason M. Melear, D.J. Andorsky, Morton Coleman, Mathias J. Rummel, Frederick Lansigan, J. Li, G.S. Nowakowski, Jeffrey P. Sharman, Suzanne R. Fanning, Abdulraheem Yacoub, and Jung Ryun Ahn

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Interim analysis, medicine.disease, Internal medicine, Relapsed refractory, Medicine, In patient, Mantle cell lymphoma, business
Published
2021
Full Text
View/download PDF

3. OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING

Author

Jay Courtright, Nikolaus S. Trede, Daanish Hoda, Habte A. Yimer, Paul Shaughnessy, J. Essell, Don A. Stevens, James Lymp, J. C. Varela, Suzanne R. Fanning, C.R. Bachier, Mohamad Cherry, Marina Youssef, Jeffrey P. Sharman, J. E. Godwin, Michael B. Maris, and B. Mattar

Subjects
Outreach, Cancer Research, medicine.medical_specialty, Oncology, business.industry, Medicine, Medical physics, Hematology, General Medicine, business
Published
2021
Full Text
View/download PDF

4. INDUCTION R 2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY

Author

S. H . Shao, Mathias J. Rummel, Mecide Gharibo, V . Parameswaran, Morton Coleman, Jeffrey P. Sharman, D.J. Andorsky, Jung Ryun Ahn, C. Reynolds, G.S. Nowakowski, Abdulraheem Yacoub, S. G . Moore, J. Li, and Frederick Lansigan

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Interim analysis, Internal medicine, Relapsed refractory, medicine, In patient, business
Published
2021
Full Text
View/download PDF

5. INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

Author

Jeffrey P. Sharman, C. Reynolds, Frederick Lansigan, Morton Coleman, Abdulraheem Yacoub, Kenneth A. Foon, Mathias J. Rummel, Jiahui Li, Kathryn S. Kolibaba, Suzanne R. Fanning, Jason M. Melear, D.J. Andorsky, and Mary Llorente

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Interim analysis, Internal medicine, Relapsed refractory, Indolent Non-Hodgkin Lymphoma, Medicine, In patient, business
Published
2019
Full Text
View/download PDF

6. MAGNIFY PHASE IIIB INTERIM ANALYSIS: FIRST REPORT OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Author

Jiahui Li, Jeffrey P. Sharman, Kenneth A. Foon, Mary Llorente, Morton Coleman, D.J. Andorsky, Frederick Lansigan, C. Reynolds, Suzanne R. Fanning, Mathias J. Rummel, Kathryn S. Kolibaba, Abdulraheem Yacoub, and Jason M. Melear

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Interim analysis, Internal medicine, Relapsed refractory, medicine, In patient, Mantle cell lymphoma, business
Published
2019
Full Text
View/download PDF

7. ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE 1/2 STUDY

Author

Kathryn S. Kolibaba, Bruce D. Cheson, Jennifer E. Vaughn, C. Di Simone, T. E. Witzig, William Jeffery Edenfield, Kami J. Maddocks, Roger M. Lyons, Habte A. Yimer, Mitul Gandhi, Helen Wei, Priti Patel, Felipe Samaniego, Julie M. Vose, Jeffrey P. Sharman, Edward M. Chan, and S. de Vos

Subjects
Cancer Research, business.industry, Hematology, General Medicine, Pembrolizumab, medicine.disease, Oncology, Phase (matter), Relapsed refractory, Cancer research, Medicine, Acalabrutinib, business, Diffuse large B-cell lymphoma
Published
2019
Full Text
View/download PDF

8. PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Author

R.K. Raman, M.M. Frigault, Kerry A. Rogers, C. Quah, John N. Allan, Morton Coleman, Philip A. Thompson, M.H. Wang, Thomas J. Kipps, Jeffrey P. Sharman, R. Izumi, and Bruce D. Cheson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Chronic lymphocytic leukemia, Phases of clinical research, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Ibrutinib, Internal medicine, Relapsed refractory, medicine, Acalabrutinib, business
Published
2019
Full Text
View/download PDF

9. UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Author

Wojciech Jurczak, Nilanjan Ghosh, James A. Reeves, Peter Sportelli, Jeffrey P. Sharman, John M. Burke, Michael S. Weiss, Ewa Lech-Marańda, P. L. Zinzani, H.P. Miskin, Bertrand Anz, Felipe Samaniego, Piotr Smolewski, C.Y. Cheah, Owen A. O'Connor, Nathan Fowler, Lori A. Leslie, Kathryn S. Kolibaba, Piers Em Patten, Julio C. Chavez, Lydia Scarfò, and Enrico Derenzini

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Marginal zone lymphoma, Phases of clinical research, Hematology, General Medicine, Internal medicine, Relapsed refractory, medicine, In patient, Open label, business
Published
2019
Full Text
View/download PDF

10. POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA

Author

Lijia Wang, Jamie Hirata, Calvin Lee, Gilles Salles, Hervé Tilly, Andy I. Chen, F. Morschhauser, Thierry Lamy, Elicia Penuel, Nancy L. Bartlett, Javier Munoz, Corinne Haioun, and Jeffrey P. Sharman

Subjects
Cancer Research, business.industry, Cyclophosphamide/doxorubicin/prednisone, Hematology, General Medicine, medicine.disease, Polatuzumab vedotin, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Cancer research, Rituximab, business, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug
Published
2017
Full Text
View/download PDF

11. EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Author

Paul M. Barr, Ian W. Flinn, S. E. Coutre, D.F. James, Constantine S. Tam, J. Ninomoto, Thomas J. Kipps, Paolo Ghia, William G. Wierda, Jan A. Burger, Jeffrey P. Sharman, Don A. Stevens, Susan O'Brien, C. Zhou, Richard R. Furman, and John C. Byrd

Subjects
Cancer Research, business.industry, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, Tumor Debulking, Tumor lysis syndrome, chemistry.chemical_compound, Oncology, chemistry, Ibrutinib, Immunology, Cancer research, Medicine, In patient, Single agent, business
Published
2017
Full Text
View/download PDF

12. PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA

Author

Morton Coleman, Jiahui Li, J.D. Bitran, Justin L. Ricker, Mary Llorente, Jeffrey P. Sharman, Frederick Lansigan, D.J. Andorsky, Abdulraheem Yacoub, Suzanne R. Fanning, H.D. Brooks, K.S. Kolibaba, Kenneth A. Foon, and Jason M. Melear

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Marginal zone lymphoma, Hematology, General Medicine, 03 medical and health sciences, 0302 clinical medicine, Refractory, 030220 oncology & carcinogenesis, Internal medicine, medicine, Rituximab, business, 030215 immunology, Lenalidomide, medicine.drug
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results